Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chung-Cheng Huang

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Scientific Reports|March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasisTzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
Targeted Oncology|February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in TaiwanPing-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
International Journal of Cancer|September 24, 2021
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutationChi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, et al.
Scientific Reports|November 21, 2023
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLCJia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLCPi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, et al.
Thoracic Cancer|April 14, 2020
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancerChia-Hsun Chu, Tzu-Hsuan Chiu, Chin-Chou Wang, et al.
Therapeutic Advances in Medical Oncology|July 28, 2022
Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis studySuey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, et al.
Vaccines|May 25, 2024
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerPing-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang, et al.
Journal of Proteome Research|December 16, 2010
Use of proteomic differential displays to assess functional discrepancies and adjustments of human bone marrow- and Wharton jelly-derived mesenchymal stem cellsHsing-Chun Kuo, Chi-Chin Chiu, Wan-Ching Chang, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Scientific Reports|March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasisTzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
Targeted Oncology|February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in TaiwanPing-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
International Journal of Cancer|September 24, 2021
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutationChi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, et al.
Scientific Reports|November 21, 2023
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLCJia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, et al.
Therapeutic Advances in Medical Oncology|January 22, 2024
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLCPi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, et al.
Thoracic Cancer|April 14, 2020
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancerChia-Hsun Chu, Tzu-Hsuan Chiu, Chin-Chou Wang, et al.
Therapeutic Advances in Medical Oncology|July 28, 2022
Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis studySuey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, et al.
Vaccines|May 25, 2024
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerPing-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang, et al.
Journal of Proteome Research|December 16, 2010
Use of proteomic differential displays to assess functional discrepancies and adjustments of human bone marrow- and Wharton jelly-derived mesenchymal stem cellsHsing-Chun Kuo, Chi-Chin Chiu, Wan-Ching Chang, et al.
Pageof 10